Compare SBSI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSI | ACRS |
|---|---|---|
| Founded | 1960 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.1M | 868.5M |
| IPO Year | 1995 | 2015 |
| Metric | SBSI | ACRS |
|---|---|---|
| Price | $32.09 | $6.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $35.33 | $10.20 |
| AVG Volume (30 Days) | 115.7K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 1.68 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $28.87 | N/A |
| Revenue Next Year | $5.82 | $4.24 |
| P/E Ratio | $19.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.32 | $1.74 |
| 52 Week High | $36.20 | $6.52 |
| Indicator | SBSI | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 63.11 |
| Support Level | $31.74 | $5.64 |
| Resistance Level | $33.37 | $6.52 |
| Average True Range (ATR) | 0.51 | 0.29 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 34.77 | 86.63 |
Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.